A Deeper Look into Fixed-Ratio Combinations of Basal Insulin and GLP-1 Receptor Agonists: What Does the Data Have to Say?

A continuing medical education activity Provided by NAMCP and AAMCN.

Treatment Advances for Challenging Patients with Type 2 Diabetes: What Managed Care Needs to Know About Fixed-Ration Combinations of Basal Insulin and GLP-1 is a three-part webinar series

This is Part 1 of the series focusing on managed care considerations in an evolving treatment landscape

This activity is an archive from the webinar held May 13, 2020

This activity is valid from June 1, 2020 to June 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi US

Description:
The ADA estimates that more than 30.3 million people in the US have diabetes. About 90-95% of adults who have diabetes have type 2 diabetes. According to the CDC, uncontrolled type 2 diabetes (T2DM) doubles a person's risk for death, and on average individuals with T2DM lose 10-15 years of life. The management of T2DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in T2DM management have given HCPs the ability to shrink this clinical practice gap. Fixed-ratio combinations of basal insulin and GLP-1 agonists have shown to improve both clinical and economic outcomes in T2DM patients, especially in challenging cases.

Upon completion of this activity, participants will be able to:

  • Quantify the clinical and economic burden of type 2 diabetes, including factors that contribute to poor patient adherence and increased costs

  • Examine evidence supporting the use of fixed-ratio GLP-1RA/basal insulin combinations as a means to overcome barriers to achieving glycemic control

  • Assess the role of fixed-ratio GLP-1RA/basal insulin combination therapies in management, particularly as it relates to more complicated T2DM patients

  • Discuss strategies to overcome barriers to the introduction and intensification of fixed-ratio therapies

     

Faculty: John Buse, MD, PhD
Professor of Medicine
Chief, Division of Endocrinology
Director, Diabetes Care Center
University of North Carolina School of Medicine
Director, NC Translational and Clinical Sciences Institute

Disclosure:

The University of North Carolina has received contracted consulting fees for services rendered by Dr. Buse and travel support for contracted activities from: Adocia, AstraZeneca, Dance Biopharm, Eli Lilly, Intarcia, MannKind, NovaTarg, Novo Nordisk, Senseonics, vTv Therapeutics, and Zafgen. Dr. Buse serves as a consultant for Cirius Therapeutics Inc, CSL Behring, Neurimmune AG, Pendulum, and Stability Health. He has received grants or research from NIH, Novo Nordisk, PCORI, Sanofi, Tolerion, and vTv Therapeutics. He owns stock in Mellitus Health, PhaseBio, Pendulum, and Stability Health. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi US

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue